London, ON – May 25, 2004 – Pharmaceutical developer Stellar International says it has signed agreements with privately owned Toronto-based Dalton Chemical Laboratories to manufacture its NeoVisc and Uracyst products. The company plans to move the manufacturing process for the products to Dalton’s facility by the end of May.
“Working with some of the world’s leading pharmaceutical companies to create new drugs and optimize the synthesis, production and sterile fill of their therapeutic candidates, Dalton is pleased to add our relationship with Stellar to our growing list of innovative customers,” says Dalton president and CEO Peter Pekos.
“Our business has grown substantially over the past few years and out-licensing agreements will push our current facility over its capacity. Dalton has the ability to meet this increased demand, as well as future demand, as our product sales increase according to our projections. In addition Dalton’s state-of-the-art facilities will also allow Stellar to meet the quality standards of our growing global customer base. This is a great opportunity for two maturing Canadian companies to enhance their presence in domestic and international markets,” said Peter Riehl, Stellar president and CEO.